SABS · SAB Biotherapeutics, Inc. · Executive Compensation
$3.17
+0.19 (+6.38%)
At close · Oct 5
Return incl. dividend (before tax)
Market Cap
$299.35M
Shares
90.99M
Volume · Oct 5
866.24K
Avg daily vol (3M)
491.66K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Rita Jain | Class II director | Appointed | 2026-01-07 |
| David Zaccardelli | Chairperson of the Board | Appointed | 2026-01-07 |
| David Zaccardelli | Class II director | Appointed | 2026-01-07 |
| Jeffrey Spragens | members of the Board of Directors | Resigned | 2025-09-30 |
| Christine Hamilton | members of the Board of Directors | Resigned | 2025-09-30 |
| Lucy To | Chief Financial Officer | Appointed | 2024-07-31 |
| Michael King, Jr. | Chief Financial Officer | Resigned | 2024-05-31 |
| Mark Conley | Interim Chief Financial Officer | Appointed | 2024-05-31 |
| Dr. Jay S. Skyler | Class I director | Appointed | 2024-05-08 |
| Christoph Bausch | Executive Vice President-Chief Operating Officer | Appointed | 2024-03-08 |
| Samuel J. Reich | Chief Executive Officer | Appointed | 2024-02-02 |
| Helen Katherine Ellias | Class II director | Appointed | 2023-11-20 |
| Michael King | Chief Financial Officer | Appointed | 2023-10-27 |
| Andrew Moin | Board of Directors | Appointed | 2023-10-02 |
| Andrew D. Moin | Board of Directors | Appointed | 2023-10-02 |
| Erick Lucera | director | Appointed | 2023-04-04 |